This #HispanicHeritageMonth, we reflect on the remarkable contributions of Hispanic leaders in #biotech and beyond. Hear from #TeamKura member Alma Ortiz on our commitment to inclusivity. #HHM24

Congratulations to our very own COO Kathy Ford for being named in the 2024 PharmaVoice 100 list, which recognizes the top 100 influential industry leaders in #biotech and drug development. Join us in congratulating Kathy on her accomplishment! More: bit.ly/4gQi6Ah

At #FierceJPM Week, CEO Troy Wilson, Ph.D., J.D. gave his insights on the Inflation Reduction Act (#IRA), including how we can move forward in the best interest of patients. View more here: kuraoncology.com/perspectives/k…

Could #menin be the key to understanding the development of NPM1-m and KMT2A-r #AML? See how Kura Oncology is investigating the potential of a menin inhibitor to advance treatments in AML: bit.ly/488rgnJ

For the fourth year, #TeamKura was proud to support TeamNEGU: Never Ever Give Up at their annual #JoyJars event in San Diego and Boston. We’re proud to join the #NEGU mission to spread joy and encourage every kid fighting cancer to Never Ever Give Up!

Thank you #TeamKura and The Leukemia & Lymphoma Society for another great annual Light the Night Boston event! We’re proud to participate in this honorable initiative that aims to bring light to the darkness of cancer. See the booth we supported and photos from the event below: #LightTheNightBoston

KOMET-008: Actively recruiting patients to study #ziftomenib, a #menin inhibitor, in combination with gilteritinib, a FLT3 inhibitor, for R/R NPM1-m #AML with FLT3 co-mutation. Learn more: bit.ly/3XnvrXW

This Friday, we will present preclinical data supporting the combination of KO-2806 with targeted therapies, including KRASG12C inhibitors and pan-RAS inhibitors, at #ENASymp24. Learn more: bit.ly/3UgLgio

Today, we will present preclinical data supporting the development of #ziftomenib for the treatment of advanced gastrointestinal stromal tumors (#GIST) at #ENASymp24. Learn more about these new findings and access the full poster: bit.ly/48mvloz

ONGOING TRIALS: Investigating the potential of #menin inhibition with #ziftomenib for patients with R/R NPM1-m or KMT2A-r #AML. Learn more about how we are advancing potential treatments in AML: bit.ly/3zl8ZXf

November is #NationalFamilyCaregiversMonth, a time to recognize and honor the dedication of countless caregivers who provide support to their loved ones with #cancer. See how Kura Oncology supports family caregivers: bit.ly/4fm3Pti

Today we announced our Q3 2024 #earnings, detailing updates on business and pipeline milestones as we approach #ASH24 and the end of the year. View the full release: bit.ly/40CyfDt Tune in to our investor webcast call today at 4:30 p.m. ET: ir.kuraoncology.com/events/event-d… $KURA

On #NationalSTEMDay, we celebrate the power of #STEM education and its impact on future generations. This year, we partnered with Life Science Cares San Diego and MANA de San Diego to provide educational resources and hands-on activities for students on #PiDay. Together, we’re shaping the future!

#TeamKura is proud to stand alongside the The Leukemia & Lymphoma Society for another great annual #LightTheNightSanDiego event! The dedication and support embody our shared mission of advancing research and advocacy for cancer patients everywhere. See photos from the event below:

Are you a passionate and motivated individual interested in creating meaningful change in the #cancer space? Consider joining #TeamKura! If our values resonate with you, check out our open positions and apply to join our team today: bit.ly/3U8HSpW #Hiring #LifeAtKura

Latest #AML research identifies NPM1-m as a foundational driver of ~30% of AMLs, underscoring the importance of knowing your patients' NPM1-m status. Explore our ongoing #clinicaltrials for NPM1-m AML: bit.ly/4fQoRR4

Today we announced a global strategic collaboration with Kyowa Kirin to develop and commercialize #ziftomenib, our selective oral menin inhibitor being investigated for the treatment of patients with #AML and other hematologic malignancies. @KyowaKirin_US ir.kuraoncology.com/news-releases/…

NEW DATA TO BE PRESENTED AT #ASH24! Don’t miss updates from the KOMET-007 #clinicaltrial investigating menin inhibitor combination therapy for newly diagnosed or R/R #AML. See our ongoing clinical trials: bit.ly/4eVFI4p

Today we announced our participation in the upcoming JMP Securities Hematology and Oncology Summit, where our CEO Troy Wilson, Ph.D., J.D. is scheduled to participate in a virtual fireside chat. Learn more and access the live webcast: ir.kuraoncology.com/news-releases/… $KURA